1. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Dürr A, Fowler CJ, et al: Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008, 71:670-676.
2. Benrud-Larson LM, Sandroni P, Schrag A, Low PA: Depressive symptoms and life satisfaction in patients with multiple system atrophy. Mov Disord 2005, 20:951-957.
3. Du JJ, Wang T, Huang P, Cui S, Gao C, Lin Y, Fu R, Zhou H, Chen S: Clinical characteristics and quality of life in Chinese patients with multiple system atrophy. Brain Behav 2018, 8:e01135.
4. Winter Y, Spottke AE, Stamelou M, Cabanel N, Eggert K, Höglinger GU, Sixel-Doering F, Herting B, Klockgether T, Reichmann H, et al: Health-related quality of life in multiple system atrophy and progressive supranuclear palsy. Neurodegener Dis 2011, 8:438-446.
5. Schrag A, Geser F, Stampfer-Kountchev M, Seppi K, Sawires M, Köllensperger M, Scherfler C, Quinn N, Pellecchia MT, Barone P, et al: Health-related quality of life in multiple system atrophy. Mov Disord 2006, 21:809-815.
6. Jecmenica-Lukic MV, Pekmezovic TD, Petrovic IN, Dragasevic NT, Kostić VS: Factors associated with deterioration of health-related quality of life in multiple system atrophy: 1-year follow-up study. Acta Neurol Belg 2018, 118:589-595.
7. Schrag A, Jenkinson C, Selai C, Mathias C, Quinn N: Testing the validity of the PDQ-39 in patients with MSA. Parkinsonism Relat Disord 2007, 13:152-156.
8. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X: Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011, 20:1727-1736.
9. Thompson AJ, Turner AJ: A Comparison of the EQ-5D-3L and EQ-5D-5L. Pharmacoeconomics 2020, 38:575-591.
10. Higginson IJ, Gao W, Saleem TZ, Chaudhuri KR, Burman R, McCrone P, Leigh PN: Symptoms and quality of life in late stage Parkinson syndromes: a longitudinal community study of predictive factors. PLoS One 2012, 7:e46327.
11. Zhang L, Cao B, Ou R, Wei QQ, Zhao B, Yang J, Wu Y, Shang H: Non-motor symptoms and the quality of life in multiple system atrophy with different subtypes. Parkinsonism Relat Disord 2017, 35:63-68.
12. Wenning GK, Tison F, Seppi K, Sampaio C, Diem A, Yekhlef F, Ghorayeb I, Ory F, Galitzky M, Scaravilli T, et al: Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord 2004, 19:1391-1402.
13. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H: The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005, 53:695-699.
14. Chen KL, Xu Y, Chu AQ, Ding D, Liang XN, Nasreddine ZS, Dong Q, Hong Z, Zhao QH, Guo QH: Validation of the Chinese Version of Montreal Cognitive Assessment Basic for Screening Mild Cognitive Impairment. J Am Geriatr Soc 2016, 64:e285-e290.
15. Dubois B, Slachevsky A, Litvan I, Pillon B: The FAB: a Frontal Assessment Battery at bedside. Neurology 2000, 55:1621-1626.
16. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967, 6:278-296.
17. Clark DB, Donovan JE: Reliability and validity of the Hamilton Anxiety Rating Scale in an adolescent sample. J Am Acad Child Adolesc Psychiatry 1994, 33:354-360.
18. Friedman JH, Alves G, Hagell P, Marinus J, Marsh L, Martinez-Martin P, Goetz CG, Poewe W, Rascol O, Sampaio C, et al: Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. Mov Disord 2010, 25:805-822.
19. Horvath K, Aschermann Z, Acs P, Deli G, Janszky J, Karadi K, Komoly S, Faludi B, Kovacs N: Test-retest validity of Parkinson's disease sleep scale 2nd version (PDSS-2). J Parkinsons Dis 2014, 4:687-691.
20. Johns MW: A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991, 14:540-545.
21. Stiasny-Kolster K, Mayer G, Schafer S, Moller JC, Heinzel-Gutenbrunner M, Oertel WH: The REM sleep behavior disorder screening questionnaire--a new diagnostic instrument. Mov Disord 2007, 22:2386-2393.
22. Luo N, Liu G, Li M, Guan H, Jin X, Rand-Hendriksen K: Estimating an EQ-5D-5L Value Set for China. Value Health 2017, 20:662-669.
23. Yang Z, Busschbach J, Liu G, Luo N: EQ-5D-5L norms for the urban Chinese population in China. Health Qual Life Outcomes 2018, 16:210.
24. Mei Y-X, Wu H, Zhang H-Y, Hou J, Zhang Z-X, Liao W, Liu X-T, Sang S-X, Mao Z-X, Yang D-B, et al: Health-related quality of life and its related factors in coronary heart disease patients: results from the Henan Rural Cohort study. Scientific reports 2021, 11:5011-5011.
25. Lin J, Xu X, Hou Y, Yang J, Shang H: Voxel-Based Meta-Analysis of Gray Matter Abnormalities in Multiple System Atrophy. Front Aging Neurosci 2020, 12:591666.
26. Zhang L, Cao B, Zou Y, Wei QQ, Ou R, Zhao B, Yang J, Wu Y, Shang H: Frontal lobe function, behavioral changes and quality of life in patients with multiple system atrophy. Restor Neurol Neurosci 2019, 37:11-19.
27. Torny F, Lacoste M, Videaud H, Chouly M, Parveau MC, Couratier P: [Comparison of quality of life in multiple system atrophy and Parkinson's disease]. Rev Neurol (Paris) 2009, 165:911-915.
28. Coon EA, Nelson RM, Sletten DM, Suarez MD, Ahlskog JE, Benarroch EE, Sandroni P, Mandrekar JN, Low PA, Singer W: Sex and gender influence symptom manifestation and survival in multiple system atrophy. Auton Neurosci 2019, 219:49-52.
29. Kluger BM, Krupp LB, Enoka RM: Fatigue and fatigability in neurologic illnesses: proposal for a unified taxonomy. Neurology 2013, 80:409-416.
30. Xu F, Wang H, Zhao Q, Huang H, Ning P, Shen Q, Xie D, Lu H, Xu Y: Fatigue prevalence and associated factors in patients with multiple system atrophy. Acta Neurol Scand 2021.
31. Meyer M, Lamare F, Asselineau J, Foubert-Samier A, Mazère J, Zanotti-Fregonara P, Rizzo G, Delamarre A, Spampinato U, Rascol O, et al: Brain 5-HT1A Receptor Binding in Multiple System Atrophy: An [(18) F]-MPPF PET Study. Mov Disord 2021, 36:246-251.
32. Lin JY, Zhang LY, Cao B, Wei QQ, Ou RW, Hou YB, Liu KC, Xu XR, Jiang Z, Gu XJ, et al: Sleep-related symptoms in multiple system atrophy: determinants and impact on disease severity. Chin Med J (Engl) 2020, 134:690-698.
33. Eschlböck S, Delazer M, Krismer F, Bodner T, Fanciulli A, Heim B, Heras Garvin A, Kaindlstorfer C, Karner E, Mair K, et al: Cognition in multiple system atrophy: a single-center cohort study. Ann Clin Transl Neurol 2020, 7:219-228.
34. Cao B, Zhao B, Wei QQ, Chen K, Yang J, Ou R, Wu Y, Shang HF: The Global Cognition, Frontal Lobe Dysfunction and Behavior Changes in Chinese Patients with Multiple System Atrophy. PLoS One 2015, 10:e0139773.
35. Kawai Y, Suenaga M, Takeda A, Ito M, Watanabe H, Tanaka F, Kato K, Fukatsu H, Naganawa S, Kato T, et al: Cognitive impairments in multiple system atrophy: MSA-C vs MSA-P. Neurology 2008, 70:1390-1396.
36. Koga S, Parks A, Uitti RJ, van Gerpen JA, Cheshire WP, Wszolek ZK, Dickson DW: Profile of cognitive impairment and underlying pathology in multiple system atrophy. Mov Disord 2017, 32:405-413.
37. Li N, Yang T, Ran W, Zhang X, Wang Y, Xu Z, Ren S, Zhao Q, Guo B, Wang S, et al: A study on the characteristics of cognitive function in patients with multiple system atrophy in China. Sci Rep 2021, 11:4995.